JP2008521796A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521796A5
JP2008521796A5 JP2007542516A JP2007542516A JP2008521796A5 JP 2008521796 A5 JP2008521796 A5 JP 2008521796A5 JP 2007542516 A JP2007542516 A JP 2007542516A JP 2007542516 A JP2007542516 A JP 2007542516A JP 2008521796 A5 JP2008521796 A5 JP 2008521796A5
Authority
JP
Japan
Prior art keywords
use according
disease
stem cells
pharmaceutical composition
neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007542516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521796A (ja
JP5294635B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2005/001275 external-priority patent/WO2006057003A2/en
Publication of JP2008521796A publication Critical patent/JP2008521796A/ja
Publication of JP2008521796A5 publication Critical patent/JP2008521796A5/ja
Application granted granted Critical
Publication of JP5294635B2 publication Critical patent/JP5294635B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007542516A 2004-11-29 2005-11-29 コポリマー1と組み合わせた、神経発生の誘発及び幹細胞治療 Expired - Fee Related JP5294635B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63116304P 2004-11-29 2004-11-29
US60/631,163 2004-11-29
US69049805P 2005-06-15 2005-06-15
US60/690,498 2005-06-15
PCT/IL2005/001275 WO2006057003A2 (en) 2004-11-29 2005-11-29 Induction of neurogenesis and stem cell therapy in combination with copolymer 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012248619A Division JP2013040204A (ja) 2004-11-29 2012-11-12 コポリマー1と組み合わせた、神経発生の誘発及び幹細胞治療

Publications (3)

Publication Number Publication Date
JP2008521796A JP2008521796A (ja) 2008-06-26
JP2008521796A5 true JP2008521796A5 (https=) 2009-01-22
JP5294635B2 JP5294635B2 (ja) 2013-09-18

Family

ID=36498362

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007542516A Expired - Fee Related JP5294635B2 (ja) 2004-11-29 2005-11-29 コポリマー1と組み合わせた、神経発生の誘発及び幹細胞治療
JP2012248619A Abandoned JP2013040204A (ja) 2004-11-29 2012-11-12 コポリマー1と組み合わせた、神経発生の誘発及び幹細胞治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012248619A Abandoned JP2013040204A (ja) 2004-11-29 2012-11-12 コポリマー1と組み合わせた、神経発生の誘発及び幹細胞治療

Country Status (7)

Country Link
US (2) US20090191173A1 (https=)
EP (1) EP1827108B1 (https=)
JP (2) JP5294635B2 (https=)
AU (1) AU2005308396B2 (https=)
CA (1) CA2588908C (https=)
ES (1) ES2541780T3 (https=)
WO (1) WO2006057003A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
EP2379087B1 (en) * 2008-12-19 2014-08-20 DePuy Synthes Products, LLC Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
EP2411504B1 (en) 2009-03-26 2017-05-10 DePuy Synthes Products, Inc. Human umbilical cord tissue cells as therapy for alzheimer's disease
AU2010289419A1 (en) * 2009-09-02 2012-03-29 The University Of Chicago Methods and systems for inducible ablation of neural cells
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CN107703292B (zh) * 2016-08-09 2019-07-12 杨琴 BrdU标记免疫荧光检测细胞增殖的改良方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2018211486A1 (en) * 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
AU2018270396B2 (en) 2017-05-15 2025-03-20 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease
KR101994640B1 (ko) 2018-03-16 2019-07-02 (주)메디노 신경줄기세포의 고효율 분리배양 방법
US20220233578A1 (en) * 2019-06-07 2022-07-28 Ramot At Tel-Aviv University Ltd. Compositions and methods of using same for tissue regeneration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6497872B1 (en) * 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6294346B1 (en) * 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1054880A1 (en) * 1998-02-13 2000-11-29 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
SE9802264D0 (sv) * 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6531130B1 (en) * 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US7037493B2 (en) * 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
DK1294390T3 (da) * 2000-06-07 2006-04-03 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
SI1459065T1 (sl) * 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
CA2473115A1 (en) * 2002-01-09 2003-07-24 Japan Science And Technology Agency Remedy for dysmnesia
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US7585843B2 (en) * 2003-10-03 2009-09-08 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides

Similar Documents

Publication Publication Date Title
JP2008521796A5 (https=)
Mohammadi et al. Dysfunction in brain-derived neurotrophic factor signaling pathway and susceptibility to schizophrenia, Parkinson's and Alzheimer's diseases
Choi et al. M2 phenotype microglia-derived cytokine stimulates proliferation and neuronal differentiation of endogenous stem cells in ischemic brain
Gouel et al. Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates
Corrigan et al. The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains
ES2569881T3 (es) Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos
Zhou et al. Pentraxin 3 contributes to neurogenesis after traumatic brain injury in mice
ES2882881T3 (es) Uso de moléculas de unión a semaforina-4D para promover la neurogénesis tras un ictus
ES2925550T3 (es) Trastornos neurodegenerativos
KR20100063719A (ko) Nap 유사 및 sal 유사 펩티드 모의체를 사용한 신경보호
WO2014098249A1 (ja) 組織修復活性組成物及びその利用
Zagrebelsky et al. Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor?
Flohr Post-lesion neural plasticity
ES2656353T3 (es) Nuevas aplicaciones de HIP/PAP o derivados de la misma
Yu et al. Synergistic and superimposed effect of bone marrow-derived mesenchymal stem cells combined with fasudil in experimental autoimmune encephalomyelitis
CN103648517A (zh) 神经保护肽
JP4685354B2 (ja) 神経細胞の再生におけるil6r/il6キメラの使用
ES2353490T3 (es) Factores de estimulación de la supervivencia neuronal dopaminérgica y sus utilizaciones.
ES2827923T3 (es) Composiciones y métodos de tratamiento durante los períodos no agudos después de una lesión neurológica del CNS
Huang et al. Clinical neurorestorative progress in traumatic brain injury
JP2007511210A5 (https=)
KR102414649B1 (ko) 에리스로포이에틴-유래된 펩타이드, 이의 제조 방법 및 이의 용도
Yuan et al. Combination of endogenous neural stem cell mobilization and lithium chloride treatment for hydrocephalus following intraventricular hemorrhage
ES2444569T3 (es) Quimera IL-6R/IL-6 para terapia de neuropatía periférica inducida por quimioterapia
JP2015147764A5 (https=)